Aequus Pharmaceuticals (CVE:AQS-OTCQB-) Chairman and CEO Doug Janzen sat down with Steve Darling from Proactive Investors Vancouver to discuss the company acquiring the Canadian rights to a line of products that help people deal with Dry Eye.
viewAequus Pharmaceuticals Inc.
Aequus Pharmaceuticals acquires Canadian rights to therapies for Dry Eye
Quick facts: Aequus Pharmaceuticals Inc.
Price: 0.195 CAD
TSX-V:AQS
Market: TSX-V
Market Cap: $21.82 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
Aequus Pharmaceuticals has the right Rx to bring new drugs to the...
Most read
Mining
Condor Gold starts drilling at Cacao, the first step towards demonstrating...
4 days, 8 hours ago
Tech
NexTech AR says its Virtual Experience Platform hosted the recent Student...
2 days, 2 hours ago
Mining
Orogen Royalties eyeing more organic royalty growth in 2021 as it updates on...
3 days, 2 hours ago
Mining
Perseus Mining transitions to multi-mine, multi-jurisdictional gold producer...
2 days, 16 hours ago
